{"id":551239,"date":"2021-07-05T16:28:01","date_gmt":"2021-07-05T16:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551239"},"modified":"2021-07-05T16:28:01","modified_gmt":"2021-07-05T16:28:01","slug":"chemotherapy-induced-neutropenia-market-is-expected-to-grow-at-a-cagr-of-176-in-the-7mm-for-the-study-period-20182030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapy-induced-neutropenia-market-is-expected-to-grow-at-a-cagr-of-176-in-the-7mm-for-the-study-period-20182030-by-delveinsight_551239.html","title":{"rendered":"Chemotherapy Induced Neutropenia Market is expected to grow at a CAGR of 1.76% in the 7MM for the Study Period (2018-2030) by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625462505.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chemotherapy Induced Neutropenia Market is expected to grow at a CAGR of 1.76% in the 7MM for the Study Period (2018-2030) by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625462505.jpeg\" alt=\"Chemotherapy Induced Neutropenia Market is expected to grow at a CAGR of 1.76% in the 7MM for the Study Period (2018-2030) by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Chemotherapy Induced Neutropenia Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chemotherapy Induced Neutropenia&nbsp;Market<\/a>&nbsp;<\/strong>report offers comprehensive coverage of the current treatment practices, pipeline drugs, Chemotherapy Induced Neutropenia market share of the individual therapies, current and forecasted CIN market size from 2018 to 2030 segmented into 7MM (the&nbsp;USA, EU5 (the UK,&nbsp;Italy,&nbsp;Spain,&nbsp;France, and&nbsp;Germany), and&nbsp;Japan).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chemotherapy Induced Neutropenia Market<\/a> report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Chemotherapy Induced Neutropenia market size of Neupogen and Neulasta was&nbsp;<strong>USD 216 million<\/strong>&nbsp;and&nbsp;<strong>USD 2,450 million<\/strong>&nbsp;in 2020 in the 7MM.<\/li>\n<li>The total estimated number of cancer patients on chemotherapy was&nbsp;<strong>1,790,618<\/strong>&nbsp;in 2020 in the 7MM.&nbsp;<\/li>\n<li>The Chemotherapy Induced Neutropenia epidemiological analysis for the US demonstrated Breast cancer accounting for the maximum number of Chemotherapy Induced Neutropenia prevalence out of various forms of cancers such as Lung cancer, Ovarian cancer, AML, Lymphoma, and others, with CIN cases in AML being the lowest.<\/li>\n<li>Surprisingly,&nbsp;Japan&nbsp;accounts for the largest Chemotherapy Induced Neutropenia prevalence after the US in the 7MM. The driving factor for the highest cases in&nbsp;Japan&nbsp;is due to the high number of colorectal cancer cases.&nbsp;<\/li>\n<li>Current treatments in the Chemotherapy Induced Neutropenia therapy market are limited to two approved biologics such as&nbsp;<strong>Neupogen&nbsp;<\/strong>(filgrastim) and&nbsp;<strong>Neulasta&nbsp;<\/strong>(pegfilgrastim) and their biosimilars.<\/li>\n<li>The Chemotherapy Induced Neutropenia market share of biologics is expected to decline owing to the entry of&nbsp;<strong>biosimilars&nbsp;<\/strong>as well as novel therapies.&nbsp;<\/li>\n<li>Major key players leading the Chemotherapy Induced Neutropenia market size growth ahead include&nbsp;<strong>Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals<\/strong>, and others.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapy, set to grab substantial CIN market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-neutropenia-cin-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-neutropenia-cin-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy Induced Neutropenia<\/strong><strong>: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Chemotherapy Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients undergoing cancer treatments with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. Some of the risk factors for CIN are older age, female gender, poor performance status, albumin level<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy Induced Neutropenia Epidemiology<\/strong><strong> Segmentation&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The Chemotherapy Induced Neutropenia market report puts forward the epidemiological analysis for the study period 2018-30 in the 7MM segmented into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total number of Patients on Chemotherapy<\/li>\n<li>Risk-specific Chemotherapy Patient Pool for CIN<\/li>\n<li>Total Incident Cases of CIN by Cancer-Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download report to understand which demographic factors are guiding the CIN epidemiology&nbsp;@&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-neutropenia-cin-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-neutropenia-cin-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chemotherapy Induced Neutropenia Pipeline<\/a><\/strong><strong> Therapies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rolontis (eflapegrastim injection): Spectrum Pharmaceuticals<\/li>\n<li>EC-18: Enzychem Lifesciences Corporation<\/li>\n<li>ALRN-6924: Aileron Therapeutics<\/li>\n<li>Romyelocel-L\/CL T-008: Cellerant Therapeutics<\/li>\n<li>Myelo001: Myelo Therapeutics<\/li>\n<li>Plinabulin: BeyondSpring Pharmaceuticals<\/li>\n<li>F-627 (Ryzneuta): Evive Biotech<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Check out for more @&nbsp;https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-neutropenia-cin-market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Chemotherapy Induced Neutropenia Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Coverage<\/strong>: 7MM (the US, EU5, and&nbsp;Japan)<\/p>\n<p style=\"text-align: justify;\"><strong>Study Period<\/strong>: 2018-30<\/p>\n<p style=\"text-align: justify;\"><strong>Key Companies:&nbsp;<\/strong>Spectrum Pharmaceuticals, Evive Biotech, Cellerant Therapeutics, BeyondSpring Pharmaceuticals, and others.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Chemotherapy Induced Neutropenia Pipeline Therapies:<\/strong>&nbsp;Rolontis (eflapegrastim injection), EC-18, ALRN-6924, Romyelocel-L\/CL T-008, Myelo001, Plinabulin, F-627 (Ryzneuta), and others.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy Induced Neutropenia Market Segmentation:<\/strong>&nbsp;By Geography, By Chemotherapy Induced Neutropenia Therapies<\/p>\n<p style=\"text-align: justify;\"><strong>Analysis<\/strong>: Comparative and conjoint analysis of Chemotherapy Induced Neutropenia emerging therapies<\/p>\n<p style=\"text-align: justify;\"><strong>Tools used<\/strong>: SWOT analysis, Conjoint Analysis, Porter&#8217;s Five Forces, PESTLE analysis, BCG Matrix analysis methods.<\/p>\n<p style=\"text-align: justify;\">Case Studies<\/p>\n<p style=\"text-align: justify;\">KOL&#8217;s Views<\/p>\n<p style=\"text-align: justify;\">Analyst&#8217;s Views<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td valign=\"bottom\">\n<p><strong>1<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>2<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Market Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>3<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>4<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Executive Summary of Chemotherapy Induced Neutropenia<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>5<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>6<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Algorithm for Diagnosis of Chemotherapy Induced Neutropenia&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>7<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>8<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia (CIN) Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>9<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>11<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Country Wise-Epidemiology of Chemotherapy Induced Neutropenia<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>10<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Treatment&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>12<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>13<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Key Endpoints of Chemotherapy Induced Neutropenia (CIN) Treatment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>14<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>15<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia: 7 Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>16<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Market Unmet Needs&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>17<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Case Reports<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>18<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>19<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Chemotherapy Induced Neutropenia Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>20<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>21<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>KOL Reviews<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>21<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>22<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>23<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td valign=\"bottom\">\n<p><strong>24<\/strong><\/p>\n<\/td>\n<td valign=\"bottom\">\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chemotherapy-induced-neutropenia-market-is-expected-to-grow-at-a-cagr-of-176-in-the-7mm-for-the-study-period-20182030-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chemotherapy-induced-neutropenia-market-is-expected-to-grow-at-a-cagr-of-176-in-the-7mm-for-the-study-period-20182030-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chemotherapy Induced Neutropenia Market DelveInsight&#8217;s&nbsp;Chemotherapy Induced Neutropenia&nbsp;Market&nbsp;report offers comprehensive coverage of the current treatment practices, pipeline drugs, Chemotherapy Induced Neutropenia market share of the individual therapies, current and forecasted CIN market size from 2018 to 2030 segmented into 7MM (the&nbsp;USA, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapy-induced-neutropenia-market-is-expected-to-grow-at-a-cagr-of-176-in-the-7mm-for-the-study-period-20182030-by-delveinsight_551239.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-551239","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551239"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}